SGC001
/ Beijing Sungen Biomedical Technology
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
November 26, 2025
A Research Study to Evaluate the Safety and Tolerability of SGC001 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=49 | Completed | Sponsor: Beijing Sungen Biomedical Technology Co., Ltd | Active, not recruiting ➔ Completed
Trial completion • Cardiovascular • Myocardial Infarction
November 26, 2025
A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction
(clinicaltrials.gov)
- P1 | N=38 | Completed | Sponsor: Beijing Sungen Biomedical Technology Co., Ltd | Active, not recruiting ➔ Completed | Trial completion date: Nov 2025 ➔ Jul 2025
Trial completion • Trial completion date • Cardiovascular • Myocardial Infarction
July 30, 2025
A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction
(clinicaltrials.gov)
- P1 | N=33 | Active, not recruiting | Sponsor: Beijing Sungen Biomedical Technology Co., Ltd
New P1 trial • Cardiovascular • Myocardial Infarction
July 25, 2025
A Research Study to Evaluate the Safety and Tolerability of SGC001 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=48 | Active, not recruiting | Sponsor: Beijing Sungen Biomedical Technology Co., Ltd
New P1 trial • Cardiovascular • Myocardial Infarction
1 to 4
Of
4
Go to page
1